Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $156.73 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
